Evidence map›Paper›PMID 39382617›Full record

ArticleJournal of neuro-oncology2025

Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.

Jordina Rincon-Torroella, Maureen Rakovec, Anita L Kalluri, Kelly Jiang, Carly Weber-Levine, Megan Parker, Divyaansh Raj, Josh Materi, Sadra Sepehri, Abel Ferres and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jordina Rincon-TorroellaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Maureen RakovecDepartment of Neurosurgery, University of Maryland Medical Medical Center, Baltimore, USA.
Anita L KalluriDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Kelly JiangDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Carly Weber-LevineDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Megan ParkerDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Divyaansh RajDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Josh MateriDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Sadra SepehriDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Abel FerresDepartment of Neurosurgery, Hospital Clínic de Barcelona, Barcelona, Spain.
Karisa C SchreckDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Iban AldecoaDepartment of Pathology, Biomedical Diagnostic Center (CDB), Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.
Calixto-Hope G LucasDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Haris I SairThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kristin J RedmondDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Matthias HoldhoffDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jon WeingartDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Henry BremDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Josep J González SánchezLaboratory of Experimental Oncological Neurosurgery, Neurosurgery Service, Hospital Clinic de Barcelona, Barcelona, Spain.
Xiaobu YeDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.
Chetan BettegowdaDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Phipps Building, Room 118, 600 N. Wolfe Street, Baltimore, MD, 21287, USA. cbetteg1@jhmi.edu.

Funding

NINDS NIH HHS 5R25NS065729
6 · The paper itself

Abstract

purposeOligodendroglioma is an adult-type diffuse glioma defined by 1p/19q codeletion and IDH1/2 mutation. Treatment includes surgery followed by observation alone in select low-grade tumors, or combination radiation and chemotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ). While prospective studies investigating treatments for molecularly defined oligodendrogliomas are ongoing, this retrospective study analyzes the relationship between adjuvant regimens and progression-free survival (PFS).

methodsAdults with IDH-mutant, 1p/19q codeleted oligodendroglioma (WHO grade 2 or 3) who underwent surgery between 2005 and 2021 were identified. Clinical data, disease characteristics, treatment, and outcomes were collected.

resultsA total of 207 patients with grade 2 and 70 with grade 3 oligodendrogliomas were identified. Median (IQR) follow-up was 57 (87) months. Patients with grade 3 tumors who received adjuvant radiation and PCV had longer median PFS (> 110 months) than patients who received radiation and TMZ (52 months, p = 0.008) or no adjuvant chemoradiation (83 months, p = 0.03), which was not seen in grade 2 tumors (p = 0.8). In multivariate analysis, patients who received PCV chemotherapy (Relative Risk [95% CI] = 0.24[0.05-1.08] and radiotherapy (0.46[0.21-1.02]) trended towards longer PFS, independently of grade.

conclusionAdjuvant radiation and PCV are associated with improved PFS over radiation with TMZ in patients with grade 3 molecularly defined oligodendrogliomas, and all-grade patients treated with PCV trended towards decreased risk of recurrence and progression. These results highlight the importance of ongoing clinical trials investigating these treatments.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsChemoradiotherapy, AdjuvantLomustineOligodendrogliomaProcarbazineTemozolomideVincristineAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisLomustineProcarbazineTemozolomideVincristine1p/19q codeletionIDH mutantMolecular oligodendrogliomaPCVTemozolomide

Identifiers

PMID39382617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.